“…While the initial reports on the incidence and prevalence of thrombotic complications were relatively small and retrospective, several larger and/or prospective studies further confirmed and extended the initial observations. [ [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] ] These studies showed the relevance of considering concomitant pulmonary embolism (PE) in patients with respiratory decline [ 9 ], the results of screening for deep vein thrombosis in acutely ill patients on normal wards [ 12 ] and critically ill patients in intensive care units [ 22 ], the impact of COVID-19 on the prevalence of catheter related thrombosis [ 6 ], differences in the incidence of thrombotic complications between the first and second wave in Europe [ 28 ] and the incidence of thrombotic complications after hospital discharge. [ 27 ] Moreover, several studies confirmed the observation made by initial publications on thrombotic complications in COVID-19 patients that a diagnosis of thromboembolism per se was associated with a more complicated in-hospital clinical course, higher incidence of admittance to the intensive care unit and higher all-cause mortality.…”